Capricor Therapeutics, Inc. (CAPR) P/E Ratio History
Historical price-to-earnings valuation from 2018 to 2018
Loading P/E history...
CAPR Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Capricor Therapeutics, Inc. (CAPR) trades at a price-to-earnings ratio of -29.5x, with a stock price of $33.94 and trailing twelve-month earnings per share of $-1.79.
The current P/E is 116% below its 5-year average of 183.6x. Over the past five years, CAPR's P/E has ranged from a low of 60.9x to a high of 340.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, CAPR trades at a 232% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, CAPR trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CAPR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CAPR P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $12B | 16.6Lowest | 0.32Best | +58%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CAPR Historical P/E Data (2018–2018)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2018 Q3 | Sun Sep 30 2018 00:00:00 GM | $10.50 | $0.07 | 150.0x | -18% |
| FY2018 Q2 | Sat Jun 30 2018 00:00:00 GM | $13.40 | $0.22 | 60.9x | -67% |
| FY2018 Q1 | Sat Mar 31 2018 00:00:00 GM | $13.60 | $0.04 | 340.0x | +85% |
Average P/E for displayed period: 183.6x
See CAPR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CAPR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CAPR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCAPR — Frequently Asked Questions
Quick answers to the most common questions about buying CAPR stock.
Is CAPR stock overvalued or undervalued?
CAPR trades at -29.5x P/E, below its 5-year average of 183.6x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CAPR's valuation compare to peers?
Capricor Therapeutics, Inc. P/E of -29.5x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is CAPR's PEG ratio?
CAPR PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2018-2018.